Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01104701 · ClinicalTrials.gov registry record · Phase 2
A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT01104701 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 121 participants.
The verdict
NCT01104701, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
The purpose of Study BCB111 is to collect efficacy, pharmacokinetic, pharmacodynamic, safety, and tolerability data in patients with type 2 diabetes to assess the feasibility of once monthly dosing of the exenatide suspension formulation.
Interventions
- DRUG exenatide once weekly
- DRUG exenatide once monthly suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01104701
The ClinicalTrials.gov registry entry for NCT01104701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which exenatide once weekly is the first listed.
NCT01104701 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01104701 about?
NCT01104701 is a clinical study titled "A Study to Examine the Efficacy, Safety and Tolerability, and Pharmacokinetics of Exenatide Once Monthly Suspension". The purpose of Study BCB111 is to collect efficacy, pharmacokinetic, pharmacodynamic, safety, and tolerability data in patients with type 2 diabetes to assess the feasibility of once monthly dosing of the exenatide suspension formulation.
What is the current status of trial NCT01104701?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2010-05. Estimated completion is 2010-12.
What interventions are being tested in trial NCT01104701?
The interventions under investigation include: exenatide once weekly (DRUG), exenatide once monthly suspension (DRUG).
Who is sponsoring clinical trial NCT01104701?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.